文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

早期脓毒症中中心静脉血氧饱和度持续降低与更高死亡率相关:ALBIOS 试验回顾性分析

Persistence of Central Venous Oxygen Desaturation During Early Sepsis Is Associated With Higher Mortality: A Retrospective Analysis of the ALBIOS Trial.
PubMed 文献 · Chest · 2018-05-19
一句话结论在 ALBIOS 试验中,初始 ScvO2 < 70% 的脓毒症患者若 6 小时时 ScvO2 仍 < 70%,其 90 天死亡率独立升高(OR 1.84),可能反映潜在心功能障碍。

该研究为 ALBIOS 试验的回顾性分析,评估早期脓毒症患者 6 小时中心静脉血氧饱和度(ScvO2)< 70% 与 90 天死亡率的关系。所有受试者均按早期目标导向治疗使 6 小时 ScvO2 ≥ 70%。在初始 ScvO2 < 70% 的 514 例患者中,6 小时 ScvO2 仍 < 70% 与 90 天死亡率独立相关(OR 1.84;95% CI 1.19-2.85;P = .007);在初始 ScvO2 ≥ 70% 的 961 例患者中无此关联(OR 1.25;95% CI 0.79-1.95;P = .357)。作者认为持续低 ScvO2 可能反映潜在心功能障碍,此类患者可能从个体化干预中获益最大。

要点

  • 初始 ScvO2 < 70% 的脓毒症患者(n = 514),6 小时 ScvO2 仍 < 70% 与 90 天死亡率独立相关(OR 1.84;95% CI 1.19-2.85;P = .007)。
  • 初始 ScvO2 ≥ 70% 的患者(n = 961),6 小时 ScvO2 < 70% 与 90 天死亡率无显著关联(OR 1.25;95% CI 0.79-1.95;P = .357)。
  • 入组时和 6 小时 ScvO2 < 70% 与心脏功能障碍病史和/或体征相关,但与疾病严重程度更高或更积极的复苏无关。
  • 所有 ALBIOS 受试者均接受早期目标导向治疗,目标为 6 小时 ScvO2 ≥ 70%。
  • 作者认为,ScvO2 < 70% 的患者可能从旨在使全身氧输送与氧耗平衡正常化的个体化干预中获益最大。

适用人群与场景

  • ALBIOS 试验纳入的脓毒症患者,无论是否接受白蛋白治疗。
  • 分析按初始 ScvO2 分层:初始 ScvO2 < 70% 者 n = 514,初始 ScvO2 ≥ 70% 者 n = 961。

诊断标准与关键阈值

  • ScvO2 < 70% 定义为低中心静脉血氧饱和度,分别在入组时和 6 小时评估。
  • 早期目标导向治疗目标为 6 小时 ScvO2 ≥ 70%。

处置流程与药物剂量

  • 所有 ALBIOS 受试者均接受早期目标导向治疗,目标为 6 小时 ScvO2 ≥ 70%, regardless of treatment assignment(白蛋白或对照)。

研究设计与关键结果

  • 研究类型:ALBIOS 试验的回顾性分析;样本量:初始 ScvO2 < 70% 组 514 例,初始 ScvO2 ≥ 70% 组 961 例。
  • 在初始 ScvO2 < 70% 的患者中,6 小时 ScvO2 < 70% 与 90 天死亡率独立相关(OR 1.84;95% CI 1.19-2.85;P = .007)。
  • 在初始 ScvO2 ≥ 70% 的患者中,6 小时 ScvO2 < 70% 与 90 天死亡率无显著关联(OR 1.25;95% CI 0.79-1.95;P = .357)。
  • 入组时和 6 小时 ScvO2 < 70% 与心脏功能障碍病史和/或体征相关,但与疾病严重程度更高或更积极的复苏无关。

证据类型、等级与局限

  • 证据类型:回顾性分析(基于 ALBIOS 随机对照试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于初始 ScvO2 < 70% 的脓毒症患者,6 小时 ScvO2 仍 < 70% 提示 90 天死亡风险更高,可能反映潜在心功能障碍。
  • 作者认为,ScvO2 < 70% 的患者可能从旨在使全身氧输送与氧耗平衡正常化的个体化干预中获益最大。

指南或共识出处

  • ALBIOS 试验(Albumin Italian Outcome Sepsis),ClinicalTrials.gov 注册号 NCT00707122。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Relevance of low (< 70%) central venous oxygen saturation (Scvo2) during early sepsis has been recently questioned by three negative trials (Protocol-Based Care for Early Septic Shock, Australasian Resuscitation in Sepsis Evaluation, and Protocolized Management in Sepsis) on early goal-directed therapy; however, subjects included in those trials had Scvo2 at enrollment as high as 71 ± 13%, 73 ± 11%, and 70 ± 12%. Here we assess the association between Scvo2 < 70% at 6 h and 90-day mortality in subjects enrolled in the Albumin Italian Outcome Sepsis (ALBIOS) trial, focusing on those with initial Scvo2 < 70%.

METHODS: Regardless of treatment assignment (to receive albumin or not), all subjects enrolled in the ALBIOS trial received early goal-directed therapy aiming for Scvo2 ≥ 70% at 6 h. Using multivariable logistic regression analyses, we tested the association between Scvo2 < 70% at 6 h and 90-day mortality in those with initial Scvo2 < 70% (n = 514) or ≥ 70% (n = 961).

RESULTS: Scvo2 < 70% at 6 h was independently associated with higher 90-day mortality in subjects with initial Scvo2 < 70% (OR, 1.84; 95% CI, 1.19-2.85; P = .007) but not in those with initial Scvo2 ≥ 70% (OR, 1.25; 95% CI, 0.79-1.95; P = .357). Scvo2 < 70% at enrollment and at 6 h was associated with history and/or signs of cardiac dysfunction but not with greater severity of disease or more aggressive resuscitation (required per protocol).

CONCLUSIONS: In the ALBIOS trial, persistence of low Scvo2 was associated with higher 90-day mortality, possibly because it reflected underlying cardiac dysfunction. Subjects with Scvo2 < 70% may benefit most from individually tailored interventions aimed at normalizing the balance between systemic oxygen delivery and consumption.

TRIAL REGISTRY: ClinicalTrials.gov; No. NCT00707122; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Protti A, Masson S, Latini R, et al. Persistence of Central Venous Oxygen Desaturation During Early Sepsis Is Associated With Higher Mortality: A Retrospective Analysis of the ALBIOS Trial. Chest. 2018. PMID: 29787743. doi:10.1016/j.chest.2018.04.043

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。